Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Changing your usual eating pattern to one that is focused on longevity can bring substantial increases in life expectancy (LE), suggests a study that involved seven countries. These dietary changes include more whole grains, legumes, and nuts and less red/processed meats, sugars, and sugar-sweetened beverages.

Eating more fibre-rich foods, less red meat and sugar may prolong life expectancy

Weight gain tied to hypertension in patients on methadone maintenance treatment

The occurrence of hypertension in patients with opioid use disorder receiving methadone maintenance treatment (MMT) is associated with weight gain, reports a study.

Weight gain tied to hypertension in patients on methadone maintenance treatment

16 Jul 2024

Pemvidutide gains MOMENTUM in phase II obesity trial

Pemvidutide, an investigational, peptide-based GLP-1/glucagon dual receptor agonist, gains traction in the booming obesity drug market, delivering significant weight loss reductions in nondiabetic individuals with overweight or obesity in the phase II MOMENTUM trial.

Pemvidutide gains MOMENTUM in phase II obesity trial

16 Jul 2024

Ph+ ALL: 1L ponatinib ups MRD-negative CR at end of induction vs imatinib

Minimal residual disease (MRD)–negative complete remission (CR) rate at end of induction is significantly higher in adult patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia (ALL) treated with ponatinib vs imatinib combined with reduced-intensity chemotherapy, results of the phase III PhALLCON trial have shown.

Ph+ ALL: 1L ponatinib ups MRD-negative CR at end of induction vs imatinib

GLP-1RA treatment for T2DM may lower risk of surgery in inflammatory bowel disease

Use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to reduce the risk of inflammatory bowel disease (IBD)-related surgery in patients with type 2 diabetes mellitus (T2DM) and concomitant ulcerative colitis (UC) or Crohn’s disease (CD), according to a retrospective study.

GLP-1RA treatment for T2DM may lower risk of surgery in inflammatory bowel disease

Tirzepatide reduces sleep apnoea severity in obese patients

Treatment with tirzepatide significantly reduced sleep apnoea severity, as shown by a reduction in apnoea-hypopnea index (AHI), among patients with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, regardless of positive airway pressure (PAP) therapy, according to two SURMOUNT-OSA trials presented at ADA 2024.

Tirzepatide reduces sleep apnoea severity in obese patients

Phase II trial of nipocalimab for Sjögren’s disease turns in promising results

15 Jul 2024 bởi

The investigational monoclonal antibody nipocalimab helped reduce the intensity of Sjögren’s disease in adults in the phase II DAHLIAS trial.

Phase II trial of nipocalimab for Sjögren’s disease turns in promising results

Tofacitinib shows good retention rates in PsA patients

Tofacitinib demonstrates safety and persistence in patients with psoriatic arthritis (PsA) who are mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs, results of a study have shown.

Tofacitinib shows good retention rates in PsA patients

15 Jul 2024

Semaglutide may improve NYHA functional class in obesity-related HFpEF

15 Jul 2024 bởi

Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) treated with semaglutide are more likely to show an improvement in NYHA functional class at 52 weeks than those who received placebo, according to a study.

Semaglutide may improve NYHA functional class in obesity-related HFpEF

15 Jul 2024

Ultraprocessed foods up risk of frailty in older women

Regular consumption of ultraprocessed foods (UPF) seems to heighten the risk of frailty in older women, reveals a study.

Ultraprocessed foods up risk of frailty in older women